Tree Line Asia Master Fund (Singapore) PTE has reportedly sold 9.10 lakh shares of Claris Lifesciences through the open market route. The shares were sold on an average price of Rs 202.78 valuing the transaction to Rs 18.45 crore.
Claris is one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.